These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 31133790)

  • 1. Dysfunction of Cellular Proteostasis in Parkinson's Disease.
    Lehtonen Š; Sonninen TM; Wojciechowski S; Goldsteins G; Koistinaho J
    Front Neurosci; 2019; 13():457. PubMed ID: 31133790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders.
    Di Domenico F; Lanzillotta C
    Adv Protein Chem Struct Biol; 2022; 132():49-87. PubMed ID: 36088079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cross-Links of Endoplasmic Reticulum Stress, Autophagy, and Neurodegeneration in Parkinson's Disease.
    Ren H; Zhai W; Lu X; Wang G
    Front Aging Neurosci; 2021; 13():691881. PubMed ID: 34168552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration.
    Perri ER; Thomas CJ; Parakh S; Spencer DM; Atkin JD
    Front Cell Dev Biol; 2015; 3():80. PubMed ID: 26779479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance.
    Remondelli P; Renna M
    Front Mol Neurosci; 2017; 10():187. PubMed ID: 28670265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.
    Stojkovska I; Wani WY; Zunke F; Belur NR; Pavlenko EA; Mwenda N; Sharma K; Francelle L; Mazzulli JR
    Neuron; 2022 Feb; 110(3):436-451.e11. PubMed ID: 34793693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Excessive Oxidative Protein Folding Is Protective in MPP(+) Toxicity-Induced Parkinson's Disease Models.
    Lehtonen Š; Jaronen M; Vehviläinen P; Lakso M; Rudgalvyte M; Keksa-Goldsteine V; Wong G; Courtney MJ; Koistinaho J; Goldsteins G
    Antioxid Redox Signal; 2016 Sep; 25(8):485-97. PubMed ID: 27139804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in
    Martinez BA; Petersen DA; Gaeta AL; Stanley SP; Caldwell GA; Caldwell KA
    J Neurosci; 2017 Nov; 37(46):11085-11100. PubMed ID: 29030433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating extracellular proteostasis capacity through the unfolded protein response.
    Genereux JC; Wiseman RL
    Prion; 2015; 9(1):10-21. PubMed ID: 25946012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson's disease.
    Zhou ZD; Selvaratnam T; Lee JCT; Chao YX; Tan EK
    Transl Neurodegener; 2019; 8():6. PubMed ID: 30740222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating Secretory Proteostasis through the Unfolded Protein Response: From Function to Therapy.
    Plate L; Wiseman RL
    Trends Cell Biol; 2017 Oct; 27(10):722-737. PubMed ID: 28647092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease.
    Martinez A; Lopez N; Gonzalez C; Hetz C
    Biol Cell; 2019 Jun; 111(6):161-168. PubMed ID: 30860281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by Endoplasmic Reticulum Stress-Induced HRD1 and Chaperones: Possible Therapeutic Targets for Alzheimer's and Parkinson's Disease.
    Nomura J; Hosoi T; Kaneko M; Ozawa K; Nishi A; Nomura Y
    Med Sci (Basel); 2016 Aug; 4(3):. PubMed ID: 29083378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
    Friesen EL; De Snoo ML; Rajendran L; Kalia LV; Kalia SK
    Parkinsons Dis; 2017; 2017():5015307. PubMed ID: 28913005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER chaperones in neurodegenerative disease: Folding and beyond.
    Garcia-Huerta P; Bargsted L; Rivas A; Matus S; Vidal RL
    Brain Res; 2016 Oct; 1648(Pt B):580-587. PubMed ID: 27134034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Proteostasis in Neurodegeneration.
    Kurtishi A; Rosen B; Patil KS; Alves GW; Møller SG
    Mol Neurobiol; 2019 May; 56(5):3676-3689. PubMed ID: 30182337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoplasmic reticulum proteostasis control and gastric cancer.
    Wang Y; Wang K; Jin Y; Sheng X
    Cancer Lett; 2019 May; 449():263-271. PubMed ID: 30776479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies targeting endoplasmic reticulum stress to improve Parkinson's disease.
    Wang D; Qu S; Zhang Z; Tan L; Chen X; Zhong HJ; Chong CM
    Front Pharmacol; 2023; 14():1288894. PubMed ID: 38026955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.